弊社製品UI-201に関する学術論文を公表

February 22nd, 2023 | プレスリリース

弊社のUI-201とTCR遺伝子改変T細胞療法の併用療法に関する臨床試験の成果が、学術論文として国際学術誌 International Journal of Cancer のオンライン版に掲載されました。

Ishihara, M, Nishida, Y, Kitano, S, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int J Cancer. 2023; 1- 13. doi:10.1002/ijc.34453
onlinelibrary.wiley.com/doi/10.1002/ijc.34453

へ戻るニュース

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.